Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down Syndrome.
Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down Syndrome.
复制标题
DOI:
10.14283/jpad.2020.35
复制
发表时间:
2021
影响因子:
--
通讯作者:
Handen BL
中科院分区:
文献类型:
--
作者:
Rafii MS;Zaman S;Handen BL
The NIH-funded Alzheimer’s Biomarker Consortium Down Syndrome (ABC-DS) and the European Horizon 21 Consortium are collecting critical new information on the natural history of Alzheimer’s Disease (AD) biomarkers in adults with Down syndrome (DS), a population genetically predisposed to developing AD. These studies are also providing key insights into which biomarkers best represent clinically meaningful outcomes that are most feasible in clinical trials. This paper considers how these data can be integrated in clinical trials for individuals with DS. The Alzheimer’s Clinical Trial Consortium - Down syndrome (ACTC-DS) is a platform that brings expert researchers from both networks together to conduct clinical trials for AD in DS across international sites while building on their expertise and experience.
登录
查看更多内容
DOI:
10.1038/s41582-018-0132-6
发表时间:
2019-03
期刊:
Nature reviews. Neurology
影响因子:
--
作者:
Lott IT;Head E
通讯作者:
Head E
DOI:
10.1111/j.1365-2788.2006.00902.x
发表时间:
2007-06-01
影响因子:
3.6
作者:
Margallo-Lana, M. L.;Moore, P. B.;Tyrer, S. P.
通讯作者:
Tyrer, S. P.
DOI:
10.1016/j.trci.2018.10.006
发表时间:
2018-01-01
期刊:
Alzheimer's & dementia (New York, N. Y.)
影响因子:
--
作者:
Strydom, Andre;Coppus, Antonia;Zetterberg, Henrik
通讯作者:
Zetterberg, Henrik
DOI:
10.1111/j.1365-2990.1984.tb00351.x
发表时间:
1984-01-01
影响因子:
5
作者:
MANN, DMA;YATES, PO;MARCYNIUK, B
通讯作者:
MARCYNIUK, B
影响因子:
8.9
作者:
Moran, Julie A.;Rafii, Michael S.;Janicki, Matthew P.
通讯作者:
Janicki, Matthew P.